Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 11-12, 2013, Pages 1414-1416

  Mancuso, A ^a   Zavaglia, C ^a   Bai, F ^a   Puoti, M ^a   Belli, L S ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARCINOMA, HEPATOCELLULAR; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; HIV INFECTIONS; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS;

EID: 84893051450     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12536     Document Type: Letter

References (9)

1. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther 2013; 37: 1132-56.
2. Liovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
3. Cheng AL, Kang YK, Tsao CJ, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-35.
4. Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54: 2055-63.
5. Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with HIV infection. Hepatology 2013; 57: 249-57.
6. Sahasrabuddhe VV, Shiels MS, McGlynn KA, et al. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2012; 15: 6226-33.
7. De Nardo P, Viscione M, Corpolongo A, et al. Treatment of recurrent hepatocellular carcinoma with Sorafenib with HIV/HCV co-infected patients in HAART: a case report. Infect Agent Cancer 2012; 7: 15.
8. Chelis L, Ntinos N, Souftas V, et al. Complete response after Sorafenib therapy for hepatocellular carcinoma in an HIV-HBV coinfected patient: possible synergy with HAART? A case report Med Oncol 2011; 28: S165-8.
9. Ozenne V, Gervais A, Peytavin G, et al. Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report. Hepatogastroenterology 2011; 58: 161-2.